D3821
地伐西匹
≥98% (HPLC), powder
别名:
(S)-N-(2,3-二氢-1-甲基-2-氧代-5-苯基-1H-1,4-苯并二氮杂-3-基)吲哚-2-甲酰胺, L-364,718, MK 329
登录查看公司和协议定价
选择尺寸
关于此项目
经验公式（希尔记法）:
C25H20N4O2
化学文摘社编号:
分子量:
408.45
MDL编号:
UNSPSC代码:
12352200
PubChem化学物质编号:
NACRES:
NA.77
质量水平
方案
≥98% (HPLC)
表单
powder
储存条件
desiccated
颜色
white to off-white
溶解性
DMSO: >5 mg/mL
创始人
Merck & Co., Inc., Kenilworth, NJ, U.S.
储存温度
2-8°C
SMILES字符串
CN1C(=O)[C@@H](NC(=O)c2cc3ccccc3[nH]2)N=C(c4ccccc4)c5ccccc15
InChI
1S/C25H20N4O2/c1-29-21-14-8-6-12-18(21)22(16-9-3-2-4-10-16)27-23(25(29)31)28-24(30)20-15-17-11-5-7-13-19(17)26-20/h2-15,23,26H,1H3,(H,28,30)/t23-/m1/s1
InChI key
NFHRQQKPEBFUJK-HSZRJFAPSA-N
一般描述
地伐西匹通过化学修饰而衍生自阿斯匹林，具有苯并二氮杂骨架。
应用
地伐西匹在人胚胎肾293T细胞和人胰腺切片中已被用作胆囊收缩素受体1（CCK1R）拮抗剂。
生化/生理作用
地伐西匹是一种CCK1受体拮抗剂。
地伐西匹是一种CCK1（CCK-A）受体拮抗剂和CCK8拮抗剂。
地伐西匹是一种胆囊收缩素受体1（CCK1R）拮抗剂。它可抑制CCK与外周型受体（CCK-A）的结合。地伐西匹可逆转胆囊收缩素八肽（CCK-8）对吗啡的拮抗作用。
特点和优势
该化合物是由Merck & Co., Inc., Kenilworth, NJ, U.S.开发的。想要浏览其他由制药公司开发的化合物以及已批准药物/候选药物清单， 请单击此处。
警示用语：
Danger
危险声明
危险分类
Acute Tox. 1 Oral
储存分类代码
6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
历史批次信息供参考:
分析证书(COA)
Lot/Batch Number
Ex vivo human pancreatic slice preparations offer a valuable model for studying pancreatic exocrine biology
Liang T, et al.
The Journal of Biological Chemistry, 292(14), 5957-5969 (2017)
Involvement of endogenous CCK and CCK1 receptors in colonic motor function
Varga G, et al.
British Journal of Pharmacology, 141(8), 1275-1284 (2004)
Effect of devazepide reversed antagonism of CCK-8 against morphine on electrical and mechanical activities of rat duodenum in vitro
Xu MY, et al.
World Journal of Gastroenterology, 4(6), 524-524 (1998)
Wenya Chen et al.
Bioscience, biotechnology, and biochemistry, 76(6), 1104-1109 (2012-07-14)
We have recently reported that oral gavage of a potato extract (Potein®) suppressed the food intake in rats. The satiating effect of the potato extract was compared in the present study to other protein sources, and the involvement of endogenous
Shannon A Metcalf et al.
Peptides, 32(6), 1296-1302 (2011-05-12)
One of the possible mechanisms by which the weight-reducing surgical procedure ileal interposition (II) works is by increasing circulating levels of lower gut peptides that reduce food intake, such as glucagon like peptide-1 and peptide YY. However, since this surgery
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持